Michael A. Fennewald

Dr. Michael A. Fennewald serves as Associate Professor in the Department of Microbiology and Immunology at Rosalind Franklin University's Chicago Medical School, with cross-appointment in the School of Graduate and Postdoctoral Studies. He has maintained continuous faculty status since joining the institution in 1988 following prior positions at University of Notre Dame and postdoctoral training at University of Chicago.

His educational background includes:

• BA in unspecified discipline from Carleton College (1973)
• PhD in Microbiology from University of Chicago (1979)
• Postdoctoral Fellowship in Biochemistry at University of Chicago (1979-1981)

Dr. Fennewald's research centers on molecular genetics of antibiotic resistance in gram-negative pathogens, with particular expertise in transposon-mediated gene transfer and integron structure-function relationships. His seminal work on Thai clinical isolates of Pseudomonas aeruginosa identified multiple resistance genes (beta-lactamases, aminoglycoside modifiers, efflux pumps) organized within mobile genetic elements, revealing critical pathways for resistance dissemination in healthcare settings.

Analysis of his publication record shows consistent focus on molecular epidemiology of resistance mechanisms across Southeast Asia, with emphasis on extended-spectrum beta-lactamases and rifampin resistance. The research demonstrates sophisticated integration of genetic, biochemical, and clinical approaches to track resistance gene evolution and transmission.

Dr. Fennewald maintains active roles in academic medicine through his teaching responsibilities and research mentorship. His laboratory investigations have contributed foundational knowledge for understanding resistance gene capture and expression in clinical pathogens, supporting evidence-based approaches to antimicrobial stewardship.

His research group operates within the university's Basic Sciences infrastructure, utilizing molecular genetics techniques to characterize resistance mechanisms in gram-negative bacterial pathogens. While specific lab facilities aren't documented, the program maintains collaborative ties with clinical partners in Thailand for isolate collection and epidemiological analysis.